New Horizon Medical Solutions has officially added AmchoPlast™, a premium amniotic-chorionic membrane product, to its leading wound care and biologics portfolio—marking a significant advancement in regenerative medicine. Engineered to support both surgical and chronic wound healing, AmchoPlast offers a natural scaffold enriched with essential growth factors and cytokines. These components are key to promoting angiogenesis, reducing inflammation, and enhancing cellular proliferation, making it a powerful solution for clinicians seeking superior wound care outcomes.

Designed with ease of use and clinical efficiency in mind, AmchoPlast is delivered sterile and ready-to-use, significantly reducing procedural preparation time and infection risk. Its biocompatibility and non-immunogenic nature make it suitable for a broad spectrum of patients and wound types. Additionally, its anti-inflammatory and anti-fibrotic properties help minimize adhesions and scarring, while accelerating tissue regeneration and epithelialization. The membrane’s flexibility and availability in multiple sizes make it easy to handle and apply with precision, reducing waste and improving consistency in care delivery.

Beyond its clinical impact, AmchoPlast is also optimized for real-world application with HCPCS-compliant Q codes that simplify billing and reimbursement. Its shelf stability at room temperature supports a wide range of care settings—from hospitals to outpatient clinics—ensuring versatility and accessibility. With this launch, New Horizon Medical Solutions not only enhances its robust regenerative product lineup but also reaffirms its commitment to innovation, provider support, and improving healing outcomes in advanced wound care.